F
URTHER real growth of transplantation will depend on the use of animal organs. an elusive goal that depends on first understanding how allografts are accepted. For nearly 50 years after Medawar l recognized rejection to he an immune reaction. an organ allograft (or xenograft) was envisioned as a defenseless island under siege in a hostile recipient sea.
THE MYSTERY OF ALLOGRAFT ACCEPTANCE
When Billingham et al e . J showed that neonatal tolerance could be induced by engrafting hematolymphopoietic donor cells into immunologically immature mice. the door to transplantation was pushed ajar. Simulation of the mouse defenseless state with recipient cytoablation 4 ultimately allowed clinical bone marrow transplantation 5 -8 which was long viewed as a replacement of the immune system (complete donor leukocyte chimerism). When histoincompatible donor bone marrow or spleen cells transplanted into mouse 9 -11 and human recipients s . 6 . 8 rejected the immunologically incompetent recipients. it appeared to be the same process in reverse that destroyed organ allografts.
The resulting unidirectional paradigm of transplantation immunology seemingly accommodated the findings following bone marrow transplantation, but it did not explain organ allograft acceptance. In 1962 to 1963, it was learned that organ rejection. which previously had been considered inexorable in noncytoablated MHC-incompatible recipi- ents. could be reversed. I2 Of equal importance, subsequent immunosuppression requirements frequently declined. 12 These two related events were promptly shown to be generic. no matter what the baseline drug or what organ. 1 3-15 Their control is the practical basis of the clinical field of transplantation. This pattern of convalescence (Fig 1) was delineated initially from experience with kidney transplantation under treatment with azathioprine and dose-maneuverable prednisone, 12 the first effective double-drug cocktail. At the time of this first report. the donor-specific nonreactivity was relative and still drug dependent. In some cases. however. the tolerance became complete. A third of 3 donor kidneys (all treated before 1964) still have function of their original allografts. II> Five (one half) of these 10 kidney recipients are currently drug free, and have been for 3 to 30 years. The cumulative time of these patients off drugs equals the time on treatment (Fig 2) . Two of the five allografts were from HLAidentical donors (top and third bars). However, two were one-haplotype mismatched (second and bottom bars), and one patient received a double-haplotype incompatible kidney from a great aunt (second from bottom).
Complete tolerance also has been observed repeatedly after HLA-mismatched cadaveric liver transplantation. 17 Among our 42 longest surviving liver recipients-now 15 to '27 years posttransplantation-12 (28%) have been drug free for as long as 16 years. II> Their cumulative time off immunosuppression is almost equal to time treated (Fig 3) .
With more potent baseline drugs. survival of all organ grafts rose in three distinct leaps over a 33-year period using azathioprine. cyclosporine (CyA). and most recently tacrolimus-based immunosuppression. I x However. the sequence and timing of immunologic confrontation and resolution did not change. It was merely better controlled.
DISORIENTATION: 1962 TO 1963
There was. in fact, no explanation whv organ allografts would ever survIve. much less routinely. By 1963. donor leukocyte chimeTlsm-the means to the end of Medawars acquired tolerance and the raISOIl d'etre of bone marrow transplantation-was eliminated bv consensus as a factor in organ acceptance. It was the beginning of a long trek in the wilderness. without a compass. m the wrong direction. 
The Dichotomy of Bone Marrow and Organ Transplantation
The remarkable disparities in treatment and outcome, ostensibly involving chimerism for bone marrow but not for organ transplantation. sustained the argument for 30 years that these two kinds of procedures were successful by divergent mechanisms. The differences (Table 1) were dependence (bone marrow, left column) vs independence on HLA matching (organ. right column). risk vs freedom from graft-vs-host disease (GVHD), the frequency with which the drug-free state could be achieved. and a semantic distinction between bone marrow tolerance on one hand and organ graft acceptance on the other. As it turned out, all of these dissimilarities were more or less dependent on a single treatment variable-recipient cytoablation for the bone marrow. but not for the organ recipient.
AN EPIPHANY: 1992
What had happened after organ transplantation was recognized in 1992 when donor leukocyte chimerism was detected in the peripheral tissues or blood of all 30 human kidney or liver recipients studied 2-1/2 to 30 years posttransplantation.14-17.25 Sampling was from blood and multiple tissue sites. The sparse chimerism. in which dendritic cells were prominent. was demonstrated with donor HLA allelespecific monoclonal antibodies. In addition. the presence of Y chromosomes in female recipients of male organs was documented with in situ hybridization. 2b Finally, donor alleles of chromosome 6 (HLA) and/or chromosome 2 (sex)
were proved with polymerase chain reaction (peR).
The Two-Way Paradigm
With this information. we postulated that clinical organ transplantation under immunosuppression involved a double immune reaction which had host-vs-graft (HVG) as well as graft-vs-host (GVH) arms (Fig 5) . The characteristic cycle of immunologic crisis and resolution that is the basis of all successflli organ transplantations was the product of this bidirectional modulation. The reciprocal neutralization of the two arms explained the blind folding and thus the poor prognostIc value of HLA. matching for organ transplantation.: 7 The cancellation effect also explained the rarity of GVHD. even with tr:Jnsplantation of lymphoid-rich organs like the liver Jnd intesttne. I .. -17 ,25.:K Because the cell traincking is hi directional. both the allograft and recipient hecome genetic composltes (Fig 6. upper panel) . In essence. the passenger leukoCYtes contamed in the organ allografts constituted a rapidly disseminated lragment ot extramedullarv donor hone marrow I shown :is a bone silhouette in 29 In the mirror image of successful bone marrow transplantation to cytoablated recipients (Fig 6, lower panel) , a previously unsuspected trace population of host leukocytes invariablv can be found. 3o . 3t With either organ or bone marrow transplantation. veto and suppressor cells, cytokine profile changes. and enhancing antibodies were viewed as derivative (and accessory) phenomena following the primarY event of mutual cell engagement (Fig 6) .
Thus. the operational principle of organ allograft acceptance bv chimerism (Fig i) was the same as in the neonatal mode!.:·J cyroablation-dependent hone marrow transpiantatlon.:· 3 ..1-X and mixed chimerism tolerance models. The iast included the parabiosis models of Martinez et al 32 
Transplant Success and Failure Redefined
Successful transplantation meant that chimerism had been introduced which might or might flot be dependent on immunosuppression for stability. Failure connoted the therapeutically uncontrollable ascendancy of a HVG or GVH reaction. The explicit warning contained in this de fin ition l4 - 16 was that quantitation of chimerism could not be used to guide drug-weaning decisions. This conclusion has sometimes gone unheeded. has not been understood. or perhaps simply has been used as a strawman for debating purposes.
Level Vs Duration of ChimerIsm
There is substantial reason to believe that the level of chimerism is less important than its duration.ls.lt> which is best illustrated by experience with hepatic transplantation. In rodent liver transplant models. the cause (chimerism) and effect (tolerance) are almost contemporaneous. In most mouse 24 premise that persistent chimerism could be increased without affecting the rate of acute rejection and without increasing the risk of GVHD. providing immunosuppression was given to both immunocyte populations equally.15.IM5 These expectations have been verified in approximately 200 cases involving all of the major organs induding the intestine.
These were in essence safety questions. The therapeutic hypothesis was quite a different matter. Here the premises were that the threat of delayed acute and chronic rejection would be reduced and that the frequency of ultimate drug independence would be increased. Full efficacy evaluation is expected to take the same 5.. to 10 years shown in Fig 8, the time frame already delineated by three decades of human experience with MHC-illcompatible liver and bone marrow transplantation. ls . lo Procedures that selectivelv alter one of the interacting arms are potentiallv hazardous. exemplitied by the historical bone marrow transplant experience with GVHD after unloading the host immune system bv cvtoablation (Fig 9.  lower panel) . Delaved multiple bone marrow infusions. currentlv being evaluated in Miami."' could be a more subtle example in which the delaved uploading of a partiallv tolerant reclpient with infused donor cells could have an increased GVHD potential. We will depend on the MiamI team tor accurate mformation about the dimenSIOns of the risk or delayed bone marrow infUSIOns in human organ reCIpients. Warnings have come from rat models in which combined bone marrow and liver transplantation done simultaneouslv under a short course of tacrolimus was well rolerated. i3 However, when the transplants were staged. the second graft (even if it was the organ) always caused lethal GVHD (Fig 10) . The naive donor leukocytes delivered to the primed rats mimicked the outcome of a parent-to-defenseless offspring FI hybrid model. 23 Persico et al 4M have shown the GVHD potential with either simultaneous or staged rat bone marrow and kidney allografts (Brown Norway -> Lewis) without any immunosuppression.
XENOTRANSPLA.NTATION
Xenotransplantation inevitably must follow guidelines imposed by the two-way paradigm.-l" The necessity for chimerism was recognized a dozen years ago by I1dstad and Sachs;'-l based on evidence from the rat ~ mouse combination.
The creation of transgenic animals is in essence an attempt to improve the cross species tissue match. designed to reduce the acute barrier of humoral rejection. This principle. with emphasis on the transfection in pigs of human complement regulatorv genes. was tirst postuiated 
Zanjani Sheep Experiments
A potential crack in the xenotransplant wall has been suggested by the experiments of Zanjani et al,54.55 using a modification of the Billingham-Brent-Medawar mouse model. At the 40-to 50-day stage of the 4-to 5-month sheep gestational period. sheep embryos were inoculated intraperitoneally with leukocytes from human fetal livers, or with human stem cells purified from adult bone marrow (Fig 11) . A handful of the sheep fetuses completed their intrauterine life in a healthy state and have a stable 5% or higher human leukocyte ch'imerism 6 to 7 years later. The chimeric bone marrow has been adoptively transferred by inoculation of other sheep fetuses. 55 
Xenogeneic Chimerism in Pigs
Is it necessary to go back so far in gestation for inoculation, or to use stem cell-rich preparations? One year ago, one of us (A.S.R.) inoculated 12 pigs with 5 x 10 9 unaltered IV human bone marrow cells a few hours after birth, with no immunosuppression (n = 2) or with subsequent tacrolimus only (n = 5) or in combination with mycophenolate (MMF) (n = 5). The best results were without immunosuppression ( Table 2) . During the ensuing year. all of the five surviving animals-now weighing 350 to 410 Ib-have had low-level blood (Fig 12) and/or bone marrow chimerism.
In related experiments in which unaltered human bone marrow was infused into cvtoreduced adult baboons (7.5 Gv total lymphoid irradiation'). human colony-forming units ~f all lineages have been grown (18 months posttransplantation) from the baboon bone marrow.~6 Our assumption is that imerspecies cellular tolerance. if it develops at all (particularly in the human --neonatal pig model), will require protracted mutual exposure of the two cell populations. When the five pigs with human chimerism were tested at 11 months. there was evidence of donor-specific hyporeactivity in three of the five animals ( Fig 13) . This had become more pronounced with time (Fig 14) . However. the critical question is whether humoral immunity will be abrogated as has been reponed by AksentiJevich et al 57 after rat --mouse xenotransplantation. In the serum of Zanjani's humanized sheep.'x antihuman endothelial antibodies were detectable with in vitro assavs. even after 2 years of stable chimerism.
. The decisive test of sheep -human transplantation could not be remotely considered without preliminary parallel study of baboonized sheep. This experIment is underwav in our laboratory after producing baboon chimerIsm In pigs rather than 10 sheep. The uitlmate prechmcaJ test will be plg-to-baboon organ transplantation. 
Adoptive Transfer of Xenogeneic Tolerance
Such experiments are difficult, expensive, and may take years. However. if a level of interspecies compatibility is achieved in the inoculated pigs. these "golden animals" could become a renewable resource that will permit colony expansion by transferring the preadapted bone marrow to supralethally irradiated adult pigs or to newborn piglets. The eventual clinical objective would be to transfer the humanized pig bone marrow to cytoablated patients in preparation for a subsequent transplantation of a chimeric organ obtained from the expanded colony (Fig 15) .
Transgenic and Chimerism Technologies Combined
Aside from the observations by Rice et al,58 there has been other evidence that chimerism alone will not ameliorate the hyperacute rejection that follows xenotransplantation be- 
SUMMARY AND CONCLUSIONS
The assumption for the last third of a century that stem cell-dflven hematolymphopoictic chimerism was irrelevant to successful conventional whole organ transplantation has prompted alternative inadequate explanations of organ allograft acceptance. This assumption clouded the hiologic meaning of successful organ as well as bone marrow transplantation, and precluded the development of a cardinal principle that accommodated all facets of transplantation.
Recognition of this error and the incorporation of the chimerism factor into a two-way paradigm have allowed previous enigmas of organ as well as bone marrow engraftment to be explained. No credible evidence has emerged to interdict this interactive concept. If the two-way paradigm is correct, it will allow the remarkable advances that have been made in basic immunology to be more meaningfully exploited for transplantation. including that of xenografts. 
FUTURE OF TRANSPLANTATION

